BRIEF-Nrx Pharmaceuticals Announces FDA Grant Of Expanded Access Protocol For Use Of D-Cycloserine-Based Nrx-101 For Augmentation Of Transcranial Magnetic Stimulation In The Treatment Of Depression

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

NRXP

0.00

June 22 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:

  • NRX PHARMACEUTICALS ANNOUNCES FDA GRANT OF EXPANDED ACCESS PROTOCOL FOR USE OF D-CYCLOSERINE-BASED NRX-101 FOR AUGMENTATION OF TRANSCRANIAL MAGNETIC STIMULATION IN THE TREATMENT OF DEPRESSION

  • NRX PHARMACEUTICALS - INITIATES PIVOTAL TRIAL OF NRX-101 FOR TMS AUGMENTATION

  • NRX PHARMACEUTICALS - TO CHARGE ONLY SHIPPING AND DATA COSTS FOR NRX-101 UNDER PROTOCOL

Source text: ID:nGNX91PngW

Further company coverage: NRXP.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.